Compugen Stock Rebounds After Analyst Sees 60% Upside

Cantor Fitzgerald sees 65% upside in high-risk, high-reward play

Compugen Ltd. (CGEN) shares rose more than 5% during Thursday's session after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and a price target of $10 per share, reflecting a 65% premium to Thursday's closing price.

Analyst Varun Kumar is "cautiously positive" and sees the stock as a high-risk, high-reward play over the next 12 to 18 months. The analyst wrote in a research note that a large biopharma firm may be willing to form a more mature and strategic partnership around COM701 after the second half of 2020 combination data and first half of 2021 single-agent data, if the results support it as a potential first-in-class agent.

In November, the company said that COM701 was "well-tolerated" in a Phase 1 clinical trial with no dose-limiting toxicities observed. The clinical trial also showed initial signs of anti-tumor activity in the heavily pretreated patient population enrolled in the study. The company has also made progress securing FDA clearance for its IND application for COM902, another immuno-oncology therapeutic antibody.

Chart showing the share price performance of Compugen Ltd. (CGEN)

From a technical standpoint, the stock rebounded from its 50-day moving average toward upper trendline resistance. The relative strength index (RSI) remains neutral with a reading of 55.27, while the moving average convergence divergence (MACD) remains in a downward trend. These indicators suggest that the stock has room for further upside, but the overall trend has remained bearish since December 2019.

Traders should watch for a breakout from an ascending triangle and trendline resistance at $6.20 to fresh highs. If the stock moves lower, traders should watch for a breakdown from the 50-day moving average and trendline support near $5.75. The pennant continuation pattern suggests that the stock could continue its trend higher over the long term, but intermediate-term technical indicators look bearish.

The author holds no position in the stock(s) mentioned except through passively managed index funds.

Take the Next Step to Invest
The offers that appear in this table are from partnerships from which Investopedia receives compensation. This compensation may impact how and where listings appear. Investopedia does not include all offers available in the marketplace.